Oncocyte Corporation (OCX)
Sector • Healthcare Industry • In Vitro & In Vivo Diagnostic Substances |
Industry • In Vitro & In Vivo Diagnostic Substances |
Sector • Healthcare |
News
Oncocyte Corporation*s Revenue Surges in Q3 2023, but Profitability Remains Elusive
Oncocyte Corporation Stumbles as Revenues Plummet 57.562% in Q2 2023, Raising Investor Alarm
Exploring the Biotech & Pharma industry plummet
The company declared revenue advance admirably at, in the fiscal second quarter of 2022
Looking into third quarter of 2017 effort, OCXs* had a similar accomplishment like a year before